Recall
FDAHealthDecember 6, 2024

Breckenridge Pharmaceutical, Inc — Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, 90-count bottles (NDC 51991-747-90) Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spai

⚠️ CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

Is this relevant to me?

Geography
Nationwide
Source agency
FDA
Category
Health
Published
December 6, 2024

Nationwide in the US

What's affected?

Product
Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, 90-count bottles (NDC 51991-747-90) Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922.
Lot code
222205C

Additional details

Lot # 222205C, exp. date 11/2025

What should I do?

Recommended action

Class II recall. Voluntary: Firm initiated Quantity affected: 163,883 bottles.

View original FDA notice →

Get Health recall alerts

Delivered to your inbox. Free. No account required.